Search NASA⌕ Search

Engineering topics

Fang, Cheng

Publications and source records attributed to Fang, Cheng.

5 records
All sourcesNASA NTRSDOE OSTI
DOE OSTI2023

Printable, emissivity-adaptive and albedo-optimized covering for year-round energy saving

Radiative cooling uses high-emissivity materials to passively cool the surface of outdoor objects, such as building roofs on hot days. The issue of overcooling with this technology on cold days can be addressed by structures with thermal emissivity that is adaptive to temperature. Despite recent advances in temperature-adaptive structures, great challenges remain in their fabrication feasibility and unoptimized solar heating that may override the radiative cooling benefit. Here, in this work, we develop a printable, emissivity-adaptive and albedo-optimized covering (PEAC) based on recyclable materials with roll-to-roll fabrication. A PEAC automatically switches its sky-window emissivity from 0.25 to 0.85 when the surface temperature exceeds a pre-set transition temperature, delivering an albedo optimized for maximal year-round energy saving or thermal comfort in a given climate.

36 MATERIALS SCIENCE↗
DOE OSTI2021

Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion

The metabolic enzyme methionine adenosyltransferase 2A (MAT2A) was recently implicated as a synthetic lethal target in cancers with deletion of the methylthioadenosine phosphorylase (MTAP) gene, which is adjacent to the CDKN2A tumor suppressor and codeleted with CDKN2A in approximately 15% of all cancers. Previous attempts to target MAT2A with small-molecule inhibitors identified cellular adaptations that blunted their efficacy. Here, we report the discovery of highly potent, selective, orally bioavailable MAT2A inhibitors that overcome these challenges. Fragment screening followed by iterative structure-guided design enabled >10 000-fold improvement in potency of a family of allosteric MAT2A inhibitors that are substrate noncompetitive and inhibit release of the product, S-adenosyl methionine (SAM), from the enzyme’s active site. We demonstrate that potent MAT2A inhibitors substantially reduce SAM levels in cancer cells and selectively block proliferation of MTAP-null cells both in tissue culture and xenograft tumors. These data supported progressing AG-270 into current clinical studies (ClinicalTrials.gov NCT03435250).

60 APPLIED LIFE SCIENCES↗